# Sermorelin vs Tesamorelin: Native GHRH(1-29) Compared to the Stabilized Analog > Sermorelin vs tesamorelin: native GHRH(1-29) is rapidly cleared (~10-12 min), while the stabilized GHRH analog tesamorelin is built for duration. The mechanism, the data, and the comparison to CJC-1295 and ipamorelin, cited. Same receptor, different durability. How native sermorelin compares to the stabilized GHRH analog tesamorelin — and to CJC-1295, ipamorelin, and direct GH — read straight from the literature. ## The short version Sermorelin vs tesamorelin comes down to durability. Both molecules push the same pituitary button — the GHRH receptor — to release growth hormone. Native sermorelin clears from the blood in about ten minutes, so its action is brief. Tesamorelin is a chemically toughened version of the same kind of hormone, built to last longer in the body, and it is the one with the visceral-fat and cognition trial data. This page compares the two, and also lines sermorelin up against ipamorelin, CJC-1295, and plain injected growth hormone — each contrast tied to its source. ## Same receptor, different durability Sermorelin vs tesamorelin is a comparison of native versus stabilized. Both act at the GHRH receptor on pituitary somatotrophs, but native GHRH(1-29) — sermorelin — is rapidly cleared, with a plasma half-life on the order of ~10-12 minutes, even though a single dose elevates serum GH for about 3 hours [3]. Tesamorelin is a stabilized synthetic GHRH analog engineered for greater durability and is the GHRH-axis molecule carrying the strongest modern body-composition and cognition trial data. In the controlled older-adult trial, the daily GHRH analog (tesamorelin) had a favorable effect on cognition, raised IGF-1 by 117%, and reduced percent body fat by 7.4% [6]. Sermorelin's research weight sits earlier, in the pediatric and aging-endocrine record [1][2]. ## Why tesamorelin carries the body-composition data The modern clinical weight in this comparison sits with tesamorelin, and it is worth being precise about why. Tesamorelin is a stabilized GHRH analog studied at scale in a specific population — HIV-associated fat accumulation — where it significantly reduced visceral adipose tissue versus placebo. It is also the molecule used in the controlled older-adult cognition trial, where a daily subcutaneous GHRH analog (1 mg before bedtime) had a favorable effect on cognition, raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%, with mild adverse events [6]. Native sermorelin has nothing equivalent in adults: its strongest controlled data are the pediatric height-velocity result [1] and the older-men 24-hour GH/IGF-1 reversal over 14 days [2]. So when a claim about sermorelin's body composition or cognition effects is made, it is usually borrowing tesamorelin's evidence — a drug-class inference, not a sermorelin-specific finding. ## What the comparison does not settle Comparing native sermorelin to the stabilized analogs clarifies durability and evidence base, but it leaves the central adult question open. Longer action does not by itself establish long-term efficacy or safety for general adult "anti-aging" use, and an Annals of Internal Medicine editorial judged growth-hormone-secretagogue use for aging "not yet ready for prime time" [5]. Because GH and IGF-1 are mitogenic (growth-promoting at the cellular level), any sustained increase across this whole class carries the same recognized theoretical oncologic-risk consideration [5]. And all of these molecules — sermorelin, tesamorelin, CJC-1295, ipamorelin — are growth hormone secretagogues prohibited in sport by WADA (S2), with dedicated detection methods [13]. The comparison sorts the chemistry; it does not convert any of them into an established adult treatment. ## Sermorelin vs ipamorelin: GHRH analog vs GHRP Sermorelin is a GHRH analog acting at the GHRH receptor on somatotrophs. Ipamorelin is a growth-hormone-releasing peptide (GHRP) that acts at the separate ghrelin/GHS receptor — a different lock entirely. Because they engage different receptors, the two classes are often studied or paired together rather than treated as substitutes. This is a mechanism contrast: same downstream goal (more GH), two independent upstream switches. ## Sermorelin vs ipamorelin: what is the difference? Sermorelin is a GHRH analog acting at the GHRH receptor on somatotrophs. Ipamorelin is a growth-hormone-releasing peptide (GHRP) that acts at the separate ghrelin/GHS receptor. Because they engage different receptors, the two classes are often studied or paired together. The practical difference is the receptor each one occupies, not the hormone they ultimately release. ## How does sermorelin differ from direct HGH injections? Direct HGH supplies exogenous growth hormone, bypassing the pituitary and overriding the body's feedback. Sermorelin acts upstream on the pituitary to prompt the body's own GH, so somatostatin and IGF-1 negative feedback remain intact and the pulsatile secretion pattern is preserved. One editorial author made exactly this argument for sermorelin as a more physiologic approach to adult GH insufficiency than recombinant GH [4]. The trade-off: sermorelin depends on a pituitary that can still respond, whereas direct HGH does not. ## How does sermorelin compare to CJC-1295? Both act at the GHRH receptor, but native GHRH(1-29) is rapidly cleared (~10-12 min half-life) [3]. Stabilizing modifications — the D-Ala2 substitution, which prolongs half-life and reduces metabolic clearance, and DAC albumin-binding technology, which underlies CJC-1295 with DAC — extend the duration of action compared with native sermorelin. CJC-1295 is, in effect, native sermorelin's chemistry problem solved for longevity in the bloodstream. --- A status-console reading of the sermorelin record — every regulatory and GH/IGF-1 fact tagged with its source and its operational state, the formerly-approved-now-compounded standing reported as filed and the thin adult anti-aging evidence flagged in plain view; no clinic behind this console and nothing here dosed, dispensed, or sold.